csirt@kutim:~/threat-intel/cve/CVE-2026-58704

Katalog CVE

CVSS 8.8 · High KEV · sudah dieksploitasi EPSS 0,59%

Kerentanan Improper Authorization pada google android. Skor CVSS 3.1 8.8 (High) menurut CISA ADP. Masuk katalog KEV CISA pada 16 September 2026, artinya sudah terbukti dieksploitasi.

Deskripsi (NVD)

In Cellular Modem, there is a possible permission bypass due to a logic error in the code. This could lead to remote (proximal/adjacent) escalation of privilege with no additional execution privileges needed. User interaction is not needed for exploitation.

Advisory KUTIM-CSIRT

Rincian

Terbit di NVD
15 September 2026
Terakhir diubah
7 Oktober 2026
Status NVD
Analyzed
CVSS 3.1
8.8 (High), sumber CISA ADP
CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-285: Improper Authorization
CWE-693: Protection Mechanism Failure
EPSS (30 hari)
0,59% peluang dieksploitasi; lebih tinggi dari 46,8% CVE lain

Known Exploited Vulnerabilities (CISA)

Nama
Google Pixel Improper Authorization Vulnerability
Masuk KEV
16 September 2026
Tenggat CISA
19 September 2026 (untuk instansi federal AS)
Ransomware
Belum tercatat
Tindakan wajib
Apply mitigations in accordance with vendor instructions, ensuring compliance with CISA’s BOD 26-04 Prioritizing Security Updates Based on Risk (see URL in Notes) guidance and CISA’s “Forensics Triage Requirements” (see URL in Notes). Follow applicable BOD 26-04 guidance for cloud services or discontinue use of the product if mitigations are unavailable. Stakeholders are responsible for evaluating each asset's internet exposure and ensuring adherence to BOD 26-04 patching guidelines.

Produk dan versi terdampak

VendorProdukVersi terdampak
google android Semua versi

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · KEV CISA · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 8 Okt 2026, 06:25 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.